Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases. The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets. *
Please click to see notes of Issued Shares.Issued Shares (excluding treasury shares)
260,295,700 (as at 30 Jun 2025)
Industry
Healthcare - Pharmaceuticals & Biotechnology - Biotechnology Industry Classification (HSIC) is provided by Hang Seng Indexes Company Limited. Please see the . (HSIC)
Health Care Industry Classification (CSIC) is provided by China Securities Indexes Co., Ltd. and only available for companies dually listed in Hong Kong and Shanghai. Please see the . (CSIC)
Listing Date
24 Dec 2018
Financial Year Ends
31 Dec 2024
Chairman
Xiong Jun
Principal Office
Room 602
No. 781, Cai Lun Road
China (Shanghai) Pilot
Free Trade Zone, the PRC
Place of Incorporation
PRC
Listing Category
Primary Listing
Primary Market
Depositary
DR Ratio
Description
Amount Outstanding
-
-
Subscription Rights per Unit
Subscription price/Strike price
Listing Date
The entitlement ratio in general represents the number of warrants required to be exercised into one share or one unit of the underlying asset (subject to any adjustments as may be necessary to reflect any capitalization, rights issue, distribution or the like).Entitlement Ratio
Subscription Period
Underlying Stock Code
Trading Currency